Loading...

SOHO 2026 Annual Meeting

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Home Posters by Code Posters by Title Authors Affiliations Topics Sessions Videos Audios Previous meetings

Topics

Select Topic

Showing 1,267 results.

Thumbnail for Myelofibrosis With Monocytosis Is Clinically and Prognostically Similar to CMML

MPN - 638

Myelofibrosis With Monocytosis Is Clinically and Prognostically Similar to CMML

Patrick Crorkin

Poster Presenter: Patrick Crorkin

Thumbnail for Preinduction With Azacitidine and Venetoclax in Newly Diagnosed Patients With Acute Myelogenous Leukemia: 3-Year Survival Update of a Comparative Study

AML - 639

Preinduction With Azacitidine and Venetoclax in Newly Diagnosed Patients With Acute Myelogenous Leukemia: 3-Year Survival Update of a Comparative Study

Maher Salamoon

Poster Presenter: Maher Salamoon

Thumbnail for The emerging role of Venetoclax in high risk newly diagnosed patients with B-cell Acute Lymphoblastic Leukemia (B-ALL)

Previous 1...47 48 49 50 51 52 53...141 Next

Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

ALL - 642

The emerging role of Venetoclax in high risk newly diagnosed patients with B-cell Acute Lymphoblastic Leukemia (B-ALL)

Maher Salamoon

Poster Presenter: Maher Salamoon

Thumbnail for Real-world practice with generic venetoclax and generic Azacitidine in Acute Myelogenous Leukemia (AML) with different risk groups

AML - 643

Real-world practice with generic venetoclax and generic Azacitidine in Acute Myelogenous Leukemia (AML) with different risk groups

Maher Salamoon

Poster Presenter: Maher Salamoon

Thumbnail for The best Venetoclax dosing schedule in high-risk Myelodysplastic Syndrome (MDS)

MDS - 644

The best Venetoclax dosing schedule in high-risk Myelodysplastic Syndrome (MDS)

Maher Salamoon

Poster Presenter: Maher Salamoon

Thumbnail for Real-World Outcomes of Imetelstat: Interrogating Safety, Efficacy, and Predictors of Response in Heavily Pretreated Lower-Risk Patients With MDS

MDS - 646

Real-World Outcomes of Imetelstat: Interrogating Safety, Efficacy, and Predictors of Response in Heavily Pretreated Lower-Risk Patients With MDS

Rami Komrokji

Poster Presenter: Rami Komrokji

Thumbnail for Primary Prophylaxis With Immunoglobulin Replacement Therapy Is Associated With Lower Cumulative Infection Burden and Healthcare Utilization in Patients With Multiple Myeloma Receiving BCMA-Directed BsAbs

MM - 647

Primary Prophylaxis With Immunoglobulin Replacement Therapy Is Associated With Lower Cumulative Infection Burden and Healthcare Utilization in Patients With Multiple Myeloma Receiving BCMA-Directed BsAbs

Patricia Lugar

Poster Presenter: Patricia Lugar

Thumbnail for Molecular Predictors of Response to Venetoclax-Based Therapy in Acute Myeloid Leukemia

AML - 648

Molecular Predictors of Response to Venetoclax-Based Therapy in Acute Myeloid Leukemia

Tabish Siddiqui

Poster Presenter: Tabish Siddiqui

Thumbnail for Ciltacabtagene autoleucel immune effector cell enterocolitis is a clonal CAR+ lymphoproliferative disorder

CT - 649

Ciltacabtagene autoleucel immune effector cell enterocolitis is a clonal CAR+ lymphoproliferative disorder

Mark Hamilton

Poster Presenter: Mark Hamilton

ePosters in

Topics Sessions

Acute Lymphoblastic Leukemia (ALL)(71)Acute Myeloid Leukemia (AML)(230)Aggressive B-Cell Lymphoma (ABCL)(114)Cellular Therapy (CT)(128)Chronic Lymphocytic Leukemia (CLL)(110)Chronic Myeloid Leukemia (CML)(55)Hodgkin Lymphoma (HL)(54)Indolent B-Cell Lymphoma (IBCL)(47)Mantle Cell Lymphoma (MCL)(23)Multiple Myeloma (MM)(234)

Previous 1 2 Next

Sponsors